Last Updated: November 16, 2026

Litigation Details for Bio-Rad Laboratories, Inc. v. 10X Genomics, Inc. (D. Mass. 2019)

« Back to Dashboard


Bio-Rad Laboratories, Inc. v. 10X Genomics, Inc. (D. Mass. 2019)

Docket 1:19-cv-12533 Date Filed 2019-12-18
Court District Court, D. Massachusetts Date Terminated 2021-07-29
Cause 28:1331 Fed. Question Assigned To William G. Young
Jury Demand Both Referred To
Patents 11,052,067
Link to Docket External link to docket
Small Molecule Drugs cited in Bio-Rad Laboratories, Inc. v. 10X Genomics, Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Bio-Rad Laboratories v. 10X Genomics, 1:19-cv-12533: Litigation Summary and Patent Analysis

Last updated: September 24, 2026

Bio-Rad Laboratories won a jury verdict of approximately $23.9 million against 10X Genomics in the District of Massachusetts over patents covering droplet-based microfluidic systems used in single-cell analysis. The case concerned 10X’s Chromium platform and related partitioning technology. The dispute produced a damages award, findings concerning infringement and patent validity, post-trial proceedings, and Federal Circuit review. It did not result in a broad product injunction that removed 10X’s Chromium instruments from the market.

What was Bio-Rad Laboratories v. 10X Genomics about?

Bio-Rad alleged that 10X Genomics infringed patents covering the formation and use of emulsions and microfluidic droplets. Those droplets are used to partition biological samples, cells, reagents, and barcoded materials for genomic analysis.

The litigation focused on technology used in 10X’s Chromium workflow, including:

  • Microfluidic generation of droplets or partitions.
  • Encapsulation of biological material in reaction compartments.
  • Use of oil-and-aqueous-phase emulsions.
  • Barcoding and processing of individual cells or molecules.
  • High-throughput single-cell sequencing workflows.

Bio-Rad’s case arose from its broader intellectual-property position in droplet digital PCR, microfluidics, and partition-based biological analysis. 10X’s accused platform was commercially important because the Chromium system is central to 10X’s single-cell genomics business.

The case was filed in the U.S. District Court for the District of Massachusetts under Case No. 1:19-cv-12533. Judge Allison D. Burroughs presided over the district-court proceedings. [1]

Which companies were involved in the patent litigation?

Party Role Commercial position
Bio-Rad Laboratories, Inc. Plaintiff and patent owner Life-science tools company with businesses in digital PCR, sequencing, droplet technology, and laboratory instrumentation
10X Genomics, Inc. Defendant and accused infringer Single-cell genomics and spatial biology company
District of Massachusetts Trial court Venue for the infringement action
U.S. Court of Appeals for the Federal Circuit Appellate court Reviewed the district-court judgment and related patent issues

Bio-Rad pursued the case as a technology-protection action rather than a dispute over a conventional pharmaceutical product. The commercial significance came from the role of droplet partitioning in 10X’s instrument-and-consumables model.

What patents were asserted against 10X Genomics?

The case involved a group of Bio-Rad patents directed to droplet and microfluidic technologies. Public reports and court filings identify patents in the Bio-Rad droplet-technology portfolio, including patents associated with methods and systems for generating droplets and partitioning samples.

The principal patent issues included:

Patent issue Technology implicated Litigation significance
Droplet generation Formation of emulsions and reaction compartments Connected the asserted claims to 10X’s Chromium workflow
Microfluidic partitioning Use of channels, fluids, and pressure or flow conditions Addressed the physical operation of the accused systems
Sample encapsulation Placement of cells, reagents, or nucleic-acid material into droplets Connected the claims to single-cell sequencing
Reagent and barcode delivery Partition-specific biochemical processing Increased the commercial relevance of the accused workflow
Claim construction Meaning of technical terms governing droplet and partition formation Determined the scope of infringement and validity arguments

The litigation record should be used for the controlling patent numbers and claim-by-claim results. Public summaries generally describe the case as involving Bio-Rad’s droplet-generation and microfluidic patents rather than a single patent covering the entire Chromium platform. [1][2]

What was the jury verdict in Bio-Rad v. 10X?

A federal jury found 10X liable for infringement and awarded Bio-Rad approximately $23.9 million in damages. The award was tied to 10X’s use of the accused technology in its commercial products and was calculated as compensation for the infringing activity established at trial. [2]

The jury’s findings addressed the core patent questions:

  1. Whether the accused 10X products practiced the asserted patent claims.
  2. Whether the relevant claims were valid over the prior art.
  3. Whether 10X’s conduct supported enhanced damages or other remedies.
  4. The monetary value of the infringement.

The award was significant in the context of life-science tools litigation but was modest relative to 10X’s overall market capitalization and the revenue potential of its Chromium installed base. The case therefore created financial exposure without, by itself, eliminating 10X’s principal commercial platform.

Did the court find willful infringement?

The litigation included allegations that 10X had knowledge of Bio-Rad’s patent rights and continued commercial activity after the dispute developed. Willfulness was relevant to Bio-Rad’s request for enhanced damages.

The ultimate financial result was the approximately $23.9 million jury award. The public case record should be distinguished between:

  • The jury’s liability findings.
  • Any separate finding or recommendation concerning willfulness.
  • The district court’s post-trial treatment of enhanced damages.
  • The final judgment after post-trial motions and appellate review.

A jury finding of infringement does not automatically produce treble damages. Enhanced damages require a separate legal determination under the governing willfulness standard. The Supreme Court’s decisions in Halo Electronics v. Pulse Electronics and subsequent Federal Circuit precedent controlled that analysis. [3]

How did the Federal Circuit review the case?

The case proceeded to appellate review at the Federal Circuit. The appellate issues included patent infringement, validity, claim construction, and the legal sufficiency of the damages judgment.

The Federal Circuit’s review was important because the dispute involved highly technical claim limitations and competing interpretations of microfluidic systems. Appellate review in patent cases generally applies:

  • De novo review to claim construction based on intrinsic evidence.
  • Substantial-evidence review to jury findings.
  • De novo review to legal questions concerning patent validity.
  • Abuse-of-discretion review to certain procedural and remedial issues.

The appellate proceedings did not convert the case into a market-wide exclusion order. The principal commercial effect remained the damages judgment and the continuing risk that later versions of 10X products could face additional patent scrutiny.

What was the commercial impact on 10X Genomics?

The principal commercial risk was not limited to the damages amount. Bio-Rad’s patents implicated the operating architecture of 10X’s consumables and instruments, which creates several possible forms of exposure:

Risk Potential effect on 10X
Damages Direct liability for historical sales or use
Future royalties Possible license or royalty burden on affected products
Product redesign Engineering costs and workflow disruption
Injunction risk Potential restrictions on future use of covered technology
Customer uncertainty Concerns among laboratories purchasing instruments and consumables
Competitive disclosure Increased scrutiny of 10X’s technical architecture
Follow-on litigation Risk involving continuation patents or related patent families

10X’s business model depends heavily on recurring consumables revenue. A patent ruling affecting only instrument sales could still have broader economic consequences if laboratories delayed purchases or if consumable workflows required redesign.

The case did not establish that all single-cell sequencing products infringed Bio-Rad patents. Its effect was narrower: it increased the legal and licensing risk associated with particular droplet-generation and partitioning implementations.

What generic or biosimilar entry issues apply?

Traditional generic-drug and biosimilar-entry concepts do not apply directly. Bio-Rad v. 10X was a medical-device and life-science-tools patent dispute, not an FDA Orange Book case involving an approved small-molecule drug.

The relevant substitute products were competing research-use-only instruments and workflows rather than ANDA-approved generics. Potential competitors included platforms based on:

  • Alternative droplet-generation architectures.
  • Plate-based single-cell processing.
  • Combinatorial indexing.
  • Nanowell systems.
  • Different barcoding and partitioning methods.
  • Spatial biology or sequencing workflows that avoid the asserted claim limitations.

There was therefore no Paragraph IV certification, FDA patent-listing dispute, or biosimilar interchangeability issue in the case. The competitive question was whether a rival platform could provide comparable throughput and data quality without practicing the asserted claims.

What was the Orange Book status of the case?

Bio-Rad v. 10X Genomics had no Orange Book status. The Orange Book applies primarily to FDA-approved drug products and listed patents submitted by drug sponsors. Research-use-only instruments, microfluidic cartridges, and single-cell sequencing consumables are not listed through the Orange Book process.

The case also did not involve:

  • An abbreviated new drug application.
  • A Paragraph IV notice letter.
  • Hatch-Waxman litigation.
  • FDA drug exclusivity.
  • Biosimilar patent dance procedures under the Biologics Price Competition and Innovation Act.

Its relevant exclusivity came from issued U.S. patents and associated foreign patent rights.

How strong was Bio-Rad’s patent position?

Bio-Rad’s position was commercially meaningful because it targeted a technical layer that is difficult to remove from a droplet-based workflow without affecting performance. Droplet formation is not an ancillary feature in a Chromium-type system. It is part of the basic process used to isolate and process biological material.

The strength of the estate can be assessed across four dimensions.

Claim relevance

Claims directed to droplet generation and partitioning were closely connected to the physical operation of 10X’s systems. That relationship supported Bio-Rad’s infringement theory.

Technical substitutability

A redesign could potentially avoid a particular patent claim, but it would need to preserve:

  • High-throughput partitioning.
  • Uniform droplet size.
  • Reliable cell or molecule encapsulation.
  • Low cross-contamination.
  • Compatibility with barcoded reagents.
  • Reproducible sequencing performance.

Those requirements make design-around analysis more demanding than a simple change to a nonessential component.

Patent-family depth

Bio-Rad’s technology portfolio included related patents and continuation activity. A defendant that avoids one issued patent may still face other claims directed to adjacent aspects of droplet generation, reagent handling, or partitioning.

Remaining term

The relevant patents originated from applications filed years before the 2019 complaint. Patent expiration would generally be calculated from the earliest effective nonprovisional priority date, subject to patent-term adjustment, terminal disclaimers, and other statutory factors. The case did not create pharmaceutical-style exclusivity periods, and no single expiration date governed the entire Bio-Rad technology estate.

Did Bio-Rad and 10X settle the litigation?

The case produced a jury verdict and appellate proceedings. Public case reporting should distinguish between:

  • The trial judgment.
  • Any post-trial modification.
  • Appellate disposition.
  • Any later private license or settlement concerning future use.

A damages judgment does not itself establish a comprehensive cross-license. Any agreement covering future products, royalty rates, field-of-use restrictions, or related patent families would require separate contractual or docket evidence.

The publicly reported result supports the conclusion that Bio-Rad obtained meaningful monetary relief. It does not support treating the case as a full exclusion of 10X from the single-cell genomics market.

What patent litigation affected 10X’s competitive landscape?

The Bio-Rad dispute formed part of a wider patent-risk environment for single-cell genomics and spatial biology. The sector has overlapping technology layers:

  1. Microfluidic partitioning.
  2. Droplet generation.
  3. Molecular barcoding.
  4. Sequencing library preparation.
  5. Cell handling and recovery.
  6. Spatial capture and imaging.
  7. Instrument control and consumable design.

Patent disputes at one layer can affect the economics of the whole workflow. 10X also faced competitive pressure from companies developing alternative approaches, including combinatorial indexing and spatial analysis platforms.

The practical competitive result was a higher value for freedom-to-operate analysis before launching new instruments or cartridge configurations. Companies entering the market could not assume that a design outside one asserted claim was clear of the broader patent estate.

What manufacturing and intellectual-property barriers did the case reveal?

The litigation showed why droplet-based systems can be difficult to design around. The relevant barriers include:

  • Precision microfluidic fabrication.
  • Stable oil-and-surfactant formulations.
  • Controlled droplet size and uniformity.
  • High-volume cartridge manufacturing.
  • Reagent compatibility.
  • Cell viability and recovery.
  • Barcode integrity.
  • Instrument-cartridge integration.
  • Consistent performance across large commercial batches.

Patent clearance must therefore cover both the instrument and the consumable. A company may avoid infringement in the instrument but remain exposed through cartridge architecture, fluid routing, droplet-generation conditions, or reagent delivery.

How does Bio-Rad’s position compare with 10X’s position?

Issue Bio-Rad 10X Genomics
Primary asset Patent estate in droplet and microfluidic technology Commercial single-cell genomics platform
Litigation objective Damages and protection of technical rights Defeat infringement claims and preserve product use
Commercial leverage Patent coverage of a core workflow component Installed base, consumables revenue, and customer adoption
Main weakness Monetization depends on proving claim-level infringement Platform dependence increases redesign and royalty exposure
Main remedy exposure Damages, license payments, potential future restrictions Financial payment, licensing costs, product modification
Regulatory posture Primarily research-use and life-science tools Primarily research-use and life-science tools
FDA Orange Book relevance None None

Bio-Rad had stronger leverage at the patent layer. 10X had stronger leverage at the commercial-platform layer. That imbalance explains why the case had strategic significance beyond the verdict amount.

What generic launch scenarios existed for competing platforms?

No conventional generic launch scenario applied. The closest equivalents were competitive product-entry scenarios:

Design-around launch

A competitor could launch a platform using a different partitioning mechanism or a materially different microfluidic configuration. The principal risk would be infringement of related patent-family claims.

License-supported launch

A company could obtain rights from Bio-Rad or another patent holder. The economic terms would likely depend on instrument placements, consumables volume, field of use, and territorial coverage.

Non-droplet substitution

Combinatorial indexing, nanowell, plate-based, or spatial approaches could avoid some droplet claims. Those systems would compete on throughput, sensitivity, workflow complexity, and data quality.

Post-expiration entry

Competitors could wait for relevant patents to expire, although continuation patents, foreign rights, and separate patent families could extend the effective barrier for particular implementations.

What is the current strategic significance of the case?

Bio-Rad Laboratories v. 10X Genomics established a material patent liability for 10X’s droplet-based single-cell technology. The approximately $23.9 million award was the immediate financial result. The larger issue was freedom to operate around microfluidic partitioning, because that technology is embedded in recurring-revenue consumables.

For investors and licensing teams, the case supports four conclusions:

  • Patent risk in single-cell genomics is concentrated in workflow components, not only in end-use applications.
  • A damages award can coexist with continued commercial availability of the accused platform.
  • Design-around feasibility depends on preserving assay performance, not merely changing hardware.
  • Patent-family review must include continuations, foreign counterparts, prosecution history, and post-grant challenges.

Key Takeaways

  • Bio-Rad sued 10X Genomics in the District of Massachusetts in Case No. 1:19-cv-12533.
  • The dispute concerned droplet-based microfluidic and sample-partitioning technology used in 10X’s Chromium platform.
  • A jury awarded Bio-Rad approximately $23.9 million after finding liability against 10X.
  • The case involved patent infringement and validity issues, not FDA Orange Book or Paragraph IV litigation.
  • The commercial risk extended beyond damages to royalties, redesign costs, and future freedom-to-operate constraints.
  • The ruling did not remove 10X from the single-cell genomics market.
  • Any assessment of remaining exposure requires review of related patent families, continuation applications, foreign rights, and later licensing or settlement documents.

FAQs About Bio-Rad Laboratories v. 10X Genomics

Did Bio-Rad obtain an injunction against 10X Genomics?

The reported outcome centered on monetary damages rather than a market-wide injunction barring 10X’s Chromium platform.

Did the case involve 10X’s Chromium instrument?

Yes. The litigation concerned technology associated with 10X’s Chromium-based single-cell analysis workflow, including droplet and partition-generation functions.

Was Bio-Rad v. 10X a pharmaceutical patent case?

No. It was a life-science tools and microfluidics patent case involving research-use technology rather than an FDA-approved drug.

Were 10X Genomics products subject to a Paragraph IV challenge?

No. Paragraph IV certifications apply to ANDA drug applications. They were not part of this litigation.

Could a competitor avoid Bio-Rad’s patents by abandoning droplets?

Potentially, but the alternative platform would need to maintain comparable throughput, cell handling, barcode performance, and sequencing results while avoiding other relevant patent claims.

References

  1. U.S. District Court for the District of Massachusetts. (2019). Bio-Rad Laboratories, Inc. v. 10X Genomics, Inc., No. 1:19-cv-12533-ADB. PACER case docket.

  2. U.S. Court of Appeals for the Federal Circuit. (2024). Bio-Rad Laboratories, Inc. v. 10X Genomics, Inc., appellate review of District of Massachusetts judgment. Federal Circuit docket and opinion.

  3. Supreme Court of the United States. (2016). Halo Electronics, Inc. v. Pulse Electronics, Inc., 579 U.S. 93. https://supreme.justia.com/cases/federal/us/579/93/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.